PROK Stock Chart & Stats
$31.10
$0.00(0.00%)
At close: 4:00 PM EDT
$31.10
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$23.10 - $63.35
Previous CloseN/A
Volume0.00
Average Volume (3M)3.37K
Market Cap
$10.16B
Enterprise Value$1.31K
Total Cash (Recent Filing)$181.56M
Total Debt (Recent Filing)$3.52M
Price to Earnings (P/E)―
Beta-3.98
Next Earnings
Nov 16, 2026EPS Estimate
-2.6Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.57
Shares Outstanding208,926,940
10 Day Avg. Volume7,970
30 Day Avg. Volume3,368
Financial Highlights & Ratios
PEG Ratio0.27
Price to Book (P/B)-0.30
Price to Sales (P/S)335.98
P/FCF Ratio-2.22
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$97.25Price Target Upside212.68% Upside
Rating ConsensusHold
Number of Analyst Covering5
EPS Forecast (FY)-11.18
Revenue Forecast (FY)$8.29M
Bulls Say, Bears Say
Bulls Say
Regulatory Pathway SupportFDA alignment on eGFR slope as a surrogate endpoint supports a potential accelerated approval route for rilparencel, which could shorten the regulatory path if clinical evidence succeeds. This provides a clearer development framework and may improve the program’s strategic value over the next several quarters.
Phase 3 Clinical ProgressEnrollment remaining on track indicates that ProKidney is advancing its pivotal clinical program toward an important efficacy readout. Continued Phase 3 execution preserves the possibility of validating rilparencel and converting the lead therapy into a commercial product.
Low Reported LeverageVery low reported debt limits interest and repayment obligations compared with a highly leveraged development-stage company. This provides some near-term balance-sheet flexibility while ProKidney funds clinical development, although it does not eliminate the need for additional capital.
Bears Say
Heavy Ongoing Cash BurnThe scale of operating and free cash outflows shows that ProKidney is not self-funding its development activities. Continued reliance on external capital can dilute existing holders or increase financing constraints, making sustained clinical execution dependent on access to new funding.
Minimal Revenue And Large LossesMinimal and volatile revenue relative to very large losses confirms that ProKidney remains pre-commercial and has not established operating scale. The company therefore lacks a recurring product revenue base to offset research and development spending over the medium term.
Persistent Negative EquityMulti-year negative equity reflects accumulated deficits and creates a meaningful structural weakness in the balance sheet. Persistent losses can pressure the asset base and reduce financial resilience, leaving future development progress more reliant on new capital or successful clinical outcomes.
ProKidney News
PROK FAQ
What was ProKidney’s price range in the past 12 months?
ProKidney lowest stock price was $23.10 and its highest was $63.35 in the past 12 months.
What is ProKidney’s market cap?
ProKidney’s market cap is $10.16B.
When is ProKidney’s upcoming earnings report date?
ProKidney’s upcoming earnings report date is Nov 16, 2026 which is in 66 days.
How were ProKidney’s earnings last quarter?
ProKidney released its earnings results on Aug 10, 2026. The company reported -$2.534 earnings per share for the quarter, missing the consensus estimate of -$2.365 by -$0.169.
Is ProKidney overvalued?
According to Wall Street analysts ProKidney’s price is currently Undervalued.
Does ProKidney pay dividends?
ProKidney does not currently pay dividends.
What is ProKidney’s EPS estimate?
ProKidney’s EPS estimate is -2.6.
How many shares outstanding does ProKidney have?
ProKidney has 208,926,940 shares outstanding.
What happened to ProKidney’s price movement after its last earnings report?
ProKidney reported an EPS of -$2.534 in its last earnings report, missing expectations of -$2.365. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of ProKidney?
Currently, no hedge funds are holding shares in MX:PROK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ProKidney Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$97.25 (212.68% Upside)
$97.25 (212.68% Upside)
Blogger Sentiment
Bullish
MX:PROK Sentiment 100%
Sector Average 61%
Sector Average 61%
Insider Transactions
Sold Shares
Worth $18.0M over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-16.28%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-33.08%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
ProKidney
ProKidney Corp. is a biotechnology firm currently in the clinical trial phase, specializing in the development of innovative cell-based treatments. Their flagship product is Renal Autologous Cell Therapy (RAC-T), a unique cellular admixture derived from a patient's own cells. RAC-T is undergoing significant clinical evaluation; it is concurrently in Phase III and Phase II trials for individuals with moderate to severe diabetic kidney disease. Furthermore, the company is conducting a Phase I clinical trial to assess RAC-T's potential for patients born with congenital anomalies affecting the kidneys and urinary tract. The company was established in 2015 and operates from its headquarters in Winston-Salem, North Carolina.
PROK Stock 12 Month Forecast
Average Price Target
$97.25
▲(212.68% Upside)